Abstract
Purpose
To evaluate a protocol for the treatment of facial dystonias.
Method
A retrospective noncomparative interventional case series of all patients who attended a specialised tertiary referral clinic between January 2000 and January 2003. At the start of treatment, patients were seen and treated at weekly intervals until their symptoms were controlled or they developed complications. The sum of the weekly doses was taken as the individual patient dose and then given at 3–4 monthly intervals as required for the individual patient. Refractory cases of spasm underwent orbicularis muscle reduction. Pretarsal spasm was treated with pretarsal botulinum toxin. If the spasm was relieved but the patient could not open their eyelids, a trial of ptosis props was undertaken and the toxin injections continued, before considering a brow suspension. If patients could not see because of a spastic Bell's phenomenon, they were given centrally acting systemic medication.
Results
Of 182 new patients, 63 (35%) required two or more sets of injections to titrate their optimum dose of toxin. Symptoms improved in 169 patients (93%). Of a total 332 new patients and follow-up patients, 47 (14%) underwent surgery during their management, 36 protractor myectomy, and 13 brow suspension. Protractor myectomy improved symptoms in 23 (64%). Brow suspension improved symptoms in 12 patients (92%).
Conclusions
The dose of botulinum toxin can be titrated to the individual patient, and the refractory cases managed satisfactorily if a logical protocol is followed.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bradley EA, Hodge DO, Bartley GB . Benign essential blepharospasm among residents of Olmsted County, Minnesota, 1976 to 1995: an epidemiological study. Ophthal Plast Reconstr Surg 2003; 19: 177–181.
Grandas F, Elston J, Quinn N, Marsden CD . Blepharospasm: review of 264 patients. J Neurol Neurosurg Psychiatry 1988; 51: 767–772.
Anderson RL, Patel BC, Holds JB, Jordan DR . Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg 1998; 14: 305–317.
Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J et al. The impact of blapharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 2002; 249: 842–846.
Elston JS . Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injection. Br J Ophthalmol 1987; 71: 664–668.
Henderson JW . Essential blepharospasm. Trans Am Ophthalmol 1956; 54: 453–454.
Reynolds DH, Smith JL, Walsh TJ . Differential section of the facial nerve for blepharospasm. Trans Am Acad Ophthalmol 1967; 71: 656–664.
Gillium WN, Anderson RL . Blepharospasm surgery: an anatomic approach. Arch Ophthalmol 1981; 99: 1056–1062.
McCord CD, Coles WH, Shore JW, Spector R, Putnam JR . Treatment of essential blepharospasm 1. Comparison of facial nerve avulsion and eyebrow–eyelid muscle stripping procedure. Arch Ophthalmol 1984; 102: 266–268.
Jones TW, Waller RR, Samples JR . Myectomy for essential blepharospasm. Mayo Clin Proc 1985; 60: 663–666.
Roggenkamper P, Nussgens Z . Frontalis suspension in the treatment of essential blepharospasm unresponsive to botulinum-toxin therapy: long-term results. Graefes Arch Clin Exp Ophthalmol 1997; 235: 486–489.
De Groot V, De Wilde F, Smet L, Tassignon MJ . Frontalis suspension combined with blapharoplasty as an effective treatment for blepharospasm associated with apraxia of eyelid opening. Ophthal Plast Reconstr Surg 2000; 16: 34–38.
Scott AB, Kennedy RA, Stubbs HA . Botulinum-A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985; 103: 347–350.
Jost WH, Kohl A . Botulinum toxin: evidence based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001; 248: 21–24.
Bates AK, Halliday BL, Bailey CS, Collin JR, Bird AC . Surgical management of essential blepharospasm. Br J Ophthalmol 1991; 75: 487–490.
Tozlovanu V, Forget R, Iancu A, Boghen D . Prolonged orbicularis oculi activity: a major factor in apraxia of lid opening. Neurology 2001; 57: 1013–1018.
Aramideh M, Ongerboer de Visser BW, Koelman JH, Speelman JD . Motor persistence of orbicularis oculi muscle in eyelid opening disorders. Neurology 1995; 45: 897–902.
Krack P, Marion MH . ‘Apraxia of eyelid opening’, a focal eyelid dystonia: clinical study of 32 patients. Mov Disord 1994; 9: 610–615.
Mackie IA . Riolan's muscle: action and indications for botulinum toxin injection. Eye 2000; 14: 347–352.
Aramideh M, Ongerboer de Visser BW, Brans JW, Koelman JH, Speelman JD . Pretarsal application of botulinum toxin for the treatment of blepharospasm. J Neurol Neurosurg Psychiatry 1995; 59: 309–311.
Siatkowski RM, Tyutyunikov A, Biglan AW, Scalise D, Genovese C, Raikow RB et al. Serum antibody production to botulinum A toxin. Ophthalmology 1993; 100: 1861–1866.
Tucha O, Naumann M, Berg D, Alders GL, Lange K . Quality of life in patients with blepharospasm. Acta Neurol Scand 2001; 103: 49–52.
Drummond GT, Hinz BJ . Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol 2001; 36: 398–403.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have no financial interest in any products or drugs discussed in this article
Rights and permissions
About this article
Cite this article
Ortisi, E., Henderson, H., Bunce, C. et al. Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases. Eye 20, 916–922 (2006). https://doi.org/10.1038/sj.eye.6702054
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6702054
